Andrx Announces Name Change to Its Cholesterol Lowering Brand Product; Settles Trademark Infringement Lawsuit with Kos Pharmaceuticals.

Business Editors/Health/Medical Writers

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--June 10, 2004

Andrx Corporation (Nasdaq:ADRX) announced that, effective June 19, 2004, Andrx will begin marketing its cholesterol-lowering brand product Altocor (lovastatin extended-release tablets) under the name Altoprev(TM). Though product labeled Altocor may remain in the distribution channel (physicians' offices, pharmacies, warehouses, etc.) through August 15, 2004, all product and promotional materials bearing the Altocor name will be withdrawn from the distribution channel by that date. Altoprev labeled product is exactly the same as Altocor labeled product in all respects including ingredients, dosage form, strengths, appearance, manufacturer, price, etc.

This name change, previously announced by Andrx, results from FDA's desire to avoid confusion in the marketplace and the litigation initiated by Kos Pharmaceuticals, Inc. alleging that the Altocor name infringes a trademark of Kos. Andrx and Kos have now settled this litigation, with Andrx making a one-time $6 million payment to Kos.

About Andrx Corporation

Andrx Corporation is a pharmaceutical company that: develops and commercializes generic versions of controlled-release brand name pharmaceuticals, using the Company's proprietary controlled-release drug delivery technologies, and generic versions of niche and immediate-release pharmaceutical products, including oral contraceptives; distributes pharmaceuticals, primarily generics, manufactured by others as well as manufactured by the Company, primarily to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices; and commercializes brand pharmaceuticals, in some instances using the Company's proprietary controlled-release drug delivery technologies.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," " plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to, the Company's dependence on a relatively small number of products; licensing revenues; the timing and outcome of patent, antitrust and other litigation; the timing and commercial success of future brand and generic product approvals and launches; the effects on it's the Company's profits and losses resulting from the change of the Altocor name to Altoprev; whether the Company will be awarded any market exclusivity period and, if so, the precise dates thereof; government regulation generally; competition; manufacturing capacities, output and quality processes; the Company's ability to develop and successfully commercialize new products; the loss of revenues from existing products; development and marketing expenses that may not result in commercially successful products; the Company's inability to obtain, or the high cost of obtaining, licenses for third party technologies; commercial obstacles to the successful introduction of brand products generally; the success of the Company's joint ventures; the impact of returns, allowances and chargebacks; product liability claims; and the absence of certainty regarding the receipt of required regulatory approvals or the timing or terms of such approvals. Andrx Corporation is also subject to other risks detailed herein or detailed from time to time in its filings with the U.S. Securities and Exchange Commission. Andrx disclaims any responsibility to update the statements contained herein.

This release and additional information about Andrx Corporation is also available on the Internet at: http://www.andrx.com.